Related Experiment Video
Updated: May 28, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and
Manish Kumar1, Abhishek Singh Sengar2, Anushree Lye3
1Centre of Biomedical Research, Raebareli Road, Lucknow, Uttar Pradesh, 226014, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.
Abstract:
Cardiotoxicity remains a major limiting factor in the clinical implementation of anthracycline chemotherapy. Though the etiology of doxorubicin-dependent heart damage has yet to be fully elucidated, the ability of doxorubicin to damage DNA and trigger oxidative stress have been heavily implicated in the pathogenesis of chemotherapy-associated cardiomyopathy. Here, we demonstrate that fibronectin type III domain-containing protein 5 (FNDC5), the precursor protein for myokine irisin, is depleted in the hearts of human cancer patients or mice exposed to chemotherapeutics. In cardiomyocytes, restoration of FNDC5 expression was sufficient to mitigate reactive oxygen species (ROS) accumulation and apoptosis following doxorubicin exposure, effects dependent on the irisin encoding domain of FNDC5 as well as signaling via the putative irisin integrin receptor. Intriguingly, we identified two parallel signaling cascades impacted by FNDC5 in cardiomyocytes: the ROS-driven intrinsic mitochondrial apoptosis pathway and the ROS-independent Ataxia Telangiectasia and Rad3-Related Protein (ATR)/Checkpoint Kinase 1 (Chk1) pathway. In fact, FNDC5 forms a co-precipitable complex with Chk1 alluding to possible intracellular actions for this canonically membrane-associated protein. Whereas FNDC5 overexpression in murine heart was cardioprotective, introduction of FNDC5-targeted shRNA into the myocardium was sufficient to trigger Bax up-regulation, ATR/Chk1 activation, oxidative stress, cardiac fibrosis, loss of ventricular function, and compromised animal survival. The detrimental impact of FNDC5 depletion on heart function could be mitigated via treatment with a Chk1 inhibitor identifying Chk1 hyperactivity as a causative factor in cardiac disease. Though our data point to the potential clinical utility of FNDC5/irisin-targeted agents in the treatment of chemotherapy-induced cardiotoxicity, we also found significant down regulation in FNDC5 expression in the hearts of aged mice that attenuated the cardioprotective impacts of FNDC5 overexpression following doxorubicin exposure. Together our data underscore the importance of FNDC5/irisin in maintenance of cardiac health over the lifespan.
Insights
Fibronectin type III domain-containing protein 5 (FNDC5) depletion exacerbates doxorubicin cardiotoxicity by activating ATR/Chk1. Restoring FNDC5 protects the heart from chemotherapy-induced damage, highlighting its therapeutic potential.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Oncology Therapeutics
Background:
- Anthracycline chemotherapy, like doxorubicin, causes cardiotoxicity, limiting its clinical use.
- Doxorubicin-induced heart damage is linked to DNA damage and oxidative stress.
- The role of specific proteins in mitigating this cardiotoxicity remains incompletely understood.
Purpose of the Study:
- To investigate the role of fibronectin type III domain-containing protein 5 (FNDC5) in doxorubicin-induced cardiotoxicity.
- To elucidate the molecular mechanisms by which FNDC5 influences cardiomyocyte survival and cardiac function.
- To explore the therapeutic potential of FNDC5/irisin in preventing chemotherapy-associated cardiomyopathy.
Main Methods:
- Assessed FNDC5 expression in human and murine hearts exposed to chemotherapeutics.
- Utilized cardiomyocytes and murine models to study FNDC5 restoration and depletion effects.
- Analyzed reactive oxygen species (ROS) accumulation, apoptosis, signaling pathways (ATR/Chk1), and cardiac function.
Main Results:
- FNDC5 is depleted in hearts affected by chemotherapeutics.
- Restoring FNDC5 in cardiomyocytes mitigates doxorubicin-induced ROS and apoptosis via irisin signaling.
- FNDC5 depletion activates the ATR/Chk1 pathway, leading to cardiac dysfunction, fibrosis, and reduced survival, which can be reversed by Chk1 inhibition.
Conclusions:
- FNDC5/irisin plays a crucial protective role against doxorubicin cardiotoxicity by modulating ROS and the ATR/Chk1 pathway.
- Targeting FNDC5/irisin or Chk1 presents a potential therapeutic strategy for chemotherapy-induced cardiotoxicity.
- Age-related FNDC5 downregulation may impair cardioprotection, emphasizing FNDC5's importance in cardiac health throughout life.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity

